You searched for "prostatic"

557 results found

Antibiotics and HoLEP

Holmium laser enucleation of the prostate (HoLEP) is an increasingly done size-independent surgical treatment for benign prostatic hypertrophy. There is currently a lack of data on perioperative antibiotic prescribing patterns for HoLEP and thus, no consensus on optimal practices. This...

A new haemostatic agent in tubeless PCNL

Tubeless percutaneous nephrolithotomy (PCNL) is increasingly being used in carefully selected patients to reduce hospital stay and analgesia requirements, especially in those with little bleeding who become stone free or have insignificant residual fragments (usually <4mm). Various agents have been...

Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer

Abiraterone acetate, the prodrug of abiraterone, blocks endogenous androgen synthesis by inhibiting cytochrome p-450c17, a critical enzyme in androgen biosynthesis. Its active D4A metabolite also has anti-tumour effects through possibly multiple mechanisms. 3-5% of men diagnosed with prostate cancer in...

Erection pills may improve heart conditions and diabetes but are underused – Prostate Cancer UK research

More than 80% of men affected by prostate cancer experience erection problems. Research in the World Journal of Men’s Health, led by Prostate Cancer UK, shows evidence that erection medication can also improve serious conditions including stroke, diabetes and enlarged...

Nurse practitioner TRUS biopsy: training and preparation

As prostate cancer rates increase, many urology departments rely on multi-professional teams to diagnose and manage patients with prostate cancer. The aim of this article is to highlight the skills, training and preparation required for nurse practitioners to undertake trans-rectal...

From overseas to the UK: initial impressions

A few years ago we published stories from three international medical graduates detailing their experience of working as registrars in the UK (https://www.urologynews.uk.com/education/trainees-forum/post/initial-impressions-of-urology-in-the-uk-from-overseas-trainees). Here are three new countries and three new opinions. Dinelle Sirjuesingh, Trinidad and Tobago Trinidad and Tobago...

Imaging and Intervention in Urinary Tract Infections and Urosepsis

Urinary tract infections (UTIs) are highly prevalent in the community and account for approximately 40% of hospital-acquired infections. Yet, they are often underestimated and under-diagnosed: as one chapter of this book is entitled, nothing is simple about acute pyelonephritis. This...

Urethroplasty: a review of indications, techniques and outcomes

Urethral stricture is the most common cause of lower urinary tract obstruction in men aged between 20 and 40, carrying an estimated overall prevalence of 0.5% in the UK [1] and results in around 17,000 hospital admissions annually [2]. Endoscopic...

Testing radical prostatectomy in men with prostate cancer and oligometastases to the bone: a randomised controlled feasibility study

Prostate cancer is the commonest cancer and the second most frequent cause of cancer death in Western men [1]. The recent STAMPEDE data suggests a median survival of just 42.1 months in the control arm of metastatic men [2]. Current...

Prostate FFIT returns to Killie

Free 12-week programme helps men affected by prostate cancer get stronger, fitter and feel more supported. Prostate Scotland and the SPFL Trust are offering 16 men affected by prostate cancer the chance to take part in a free 12-week health...

Prostate cancer now England’s most common cancer

Prostate cancer cases overtook those of breast cancer by thousands in both 2022 and 2023, according to Prostate Cancer UK analysis of NHS data. Huge increase shows that more men than ever before are learning about their risk and taking...

Prostate biopsy and survival

Talk to many urologists and the axiom is “you are more likely to die with prostate cancer than from it”. This study was conducted on Danish men between 1995 and 2011. The observations are: 1) Cumulative prostate cancer – specific...